Schizophrenia Bulletin Index—1984-85

Author Index

A

Abrams, R. Genetic studies of the schizo-affective syndrome: A selective review, 10(1):26-29, 1984.
Alpert, M.; *see* Mayer, M.
Alphs, L.D.; *see* Carpenter, W.T., Jr.
Andreasen, N.C. Positive vs. negative schizophrenia: A critical evaluation, 11(3):380-389, 1985.
Andrews, G.; *see* Hall, W.
Arora, R.C.; *see* Meltzer, H.Y.
Ayalon, M., and Merom, H. The teacher interview, 11(1):117-120, 1985.
Ayalon, M.; *see* Silberman, E.K.
Aylward, E.; Walker, E.; and Bettes, B. Intelligence in schizophrenia: Meta-analysis of the research, 10(3):430-459, 1984.

B

Balogh, D.W.; *see* Merritt, R.D.
Bartels, R.; *see* Hall, W.
Beels, C.C.; Gutwirth, L.; Berkeley, J.; and Struening, E. Measurements of social support in schizophrenia, 10(3):399-411, 1984.
Bellak, L. ADD psychosis as a separate entity, 11(4):523-527, 1985.
Berenbaum, H.; *see* Oltmanns, T.F.
Berkeley, J.; *see* Beels, C.C.
Berkowitz, R.; Eberlein-Fries, R.; Kuipers, L.; and Leff, J. Educating relatives about schizophrenia, 10(3):418-429, 1984.
Bernstein, A.S.; Riedel, J.A.; Pava, J.; Schnur, D.; and Lubowsky, J. A limiting factor in the "normalization" of schizophrenic orienting response dysfunction, 11(2):230-254, 1985.
Bettes, B.; *see* Aylward, E.
Bilder, R.M.; Mukherjee, S.; Rieder, R.O.; and Pandurangi, A.K. Symptomatic and neuropsychological components of defect states, 11(3):409-419, 1985.
Bilder, R.M.; *see* Mukherjee, S.
Bleuler, M. What is schizophrenia?, 10(1):8-10, 1984.
Bockes, Z. First person account: "Freedom" means knowing you have a choice, 11(3):487-489, 1985.
Bonwitt, L. A narrative account of contacts with two study subjects, 11(1):129-137, 1985.
Braden, W. Vulnerability and schizo-affective psychosis: A two-factor model, 10(1):71-86, 1984.
Breznitz, S. Chores as a buffer against risky interaction, 11(3):357-360, 1985.
Burack, C.M.; *see* Marcus, J.
Burnam, M.A.; *see* Karno, M.
Byhouwer, B.; *see* Marcus, J.

C

Cadet, J.L. Disorders of the isodendritic core of the brainstem, 10(1):1-3, 1984.
Carpenter, W.T., Jr. Reply to Rifkin, 10(3):369-370, 1984.
Carpenter, W.T., Jr. A perspective on the psychotherapy of schizophrenia project, 10(4)599-603, 1984.
Carpenter, W.T., Jr.; Heinrichs, D.W.; and Alphs, L.D. Treatment of negative symptoms, 11(3):440-452, 1985.
Carpenter, W.T., Jr., and Pulver, A.E. Authors' reply to Helzer and Robins (Letter to the Editor), 10(1):5-7, 1984.
Carpenter, W.T., Jr.; *see* Heinrichs, D.W.
Carpenter, W.T., Jr.; *see* Pulver, A.E.
Chaika, E., and Lambe, R. The locus of dysfunction in schizophrenic speech, 11(1):8-15, 1985.
Cole, J.O.; *see* Gibbons, R.D.
Cornblatt, B.A.; Lenzenweger, M.F.; Dworkin, R.H.; and Erlenmeyer-Kimling, L. Positive and negative schizophrenic symptoms, attention, and information processing, 11(3):397-408, 1985.
Crow, T.J. The two-syndrome concept: Origins and current status, 11(3):471-486, 1985.

D

Davis, J.M.; *see* Gibbons, R.D.
Dawson, M.E., and Nuechterlein, K.H. Psychophysiological dysfunctions in the developmental course of schizophrenic disorders, 10(2):204-232, 1984.
Dawson, M.E.; *see* Nuechterlein, K.H.
Docherty, J.P. O tempora, o mores: Directions in research on the psychotherapeutic treatment of schizophrenia, 10(4):621-623, 1984.
Dunlop, S.R.; *see* Oltmanns, T.F.
Dworkin, R.H.; *see* Cornblatt, B.A.

E

Eberlein-Fries, R.; *see* Berkowitz, R.

Empfield, M.; *see* Mayer, M.
Erlenmeyer-Kimling, L.; *see* Cornblatt, B.A.
Escobar, J.; *see* Karno, M.

F

Falloon, I.R.H. The author replies to Karon (Letter to the Editor), 11(1):17–18, 1985.
Falloon, I.R.H. Developing and maintaining adherence to long-term drug-taking regimens, 10(3):412–417, 1984.
Falloon, I.R.H. Relapse: A reappraisal of assessment of outcome in schizophrenia, 10(2):293–299, 1984.
Frances, A. Validating schizotypal personality disorder: Problems with the schizophrenia connection, 11(4):595–597, 1985.
Frank, A.F.; *see* Gunderson, J.G.
Frank, A.F.; *see* Stanton, A.H.
Frosch, J.P.; *see* Gunderson, J.G.

G

Garbutt, J.C. Author's reply to Mukherjee (Letter to the Editor), 10(2):152–153, 1984.
Garmezy, N. The NIMH-Israeli high-risk study: Commendation, comments, and cautions, 11(3):349–353, 1985.
George, L., and Neufeld, R.W.J. Cognition and symptomatology in schizophrenia, 11(2):264–285, 1985.
Gibbons, R.D.; Lewine, R.R.J.; Davis, J.M.; Schooler, N.R.; and Cole, J.O. An empirical test of a Kraepelinian vs. a Bleulerian view of negative symptoms, 11(3):390–396, 1985.
Glueck, Z.; *see* Nagler, S.
Goldberg, E. Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia, 11(2):255–263, 1985.
Goldberg, S.C. Negative and deficit symptoms in schizophrenia do respond to neuroleptics, 11(3):453–456, 1985.
Goldstein, G., *see* Hall, W.
Goodnick, P.J., and Meltzer, H.Y. Treatment of schizoaffective disorders, 10(1):30–48, 1984.
Grossman, L.S.; *see* Harrow, M.
Gunderson, J.G., and Frank, A.F. The authors reply [to Herz] (Letter to the Editor), 11(4):529–531, 1985.
Gunderson, J.G.; Frank, A.F.; Katz, H.M.; Vannicelli, M.L.; Frosch, J.P.; and Knapp, P.H. Effects of psychotherapy in schizophrenia: II. Comparative outcome of two forms of treatment, 10(4):564–598, 1984.
Gunderson, J.G., and Siever, L.J. Relatedness of schizotypal to schizophrenic disorders, Editors' Introduction, 11(4):532–537, 1985.
Gunderson, J.G.; *see* Stanton, A.H.
Gutwirth, L.; *see* Beels, C.C.

H

Hall, W.; Goldstein, G.; Andrews, G.; Lapsley, H.; Bartels, R.; and Silove, D. Estimating the economic costs of schizophrenia, 11(4):598–611, 1985.
Hanlon, T.E.; *see* Heinrichs, D.W.
Hans, S.L.; *see* Marcus, J.
Haracz, J.L. Neural plasticity in schizophrenia, 11(2):191–229, 1985.
Harding, C.M.; *see* Strauss, J.S.
Harrow, M., and Grossman, L.S. Outcome in schizoaffective disorders: A critical review and reevaluation of the literature, 10(1):87–108, 1984.
Harrow, M.; *see* Lanin-Kettering, I.
Harrow, M.; *see* Pogue-Geile, M.F.
Harrow, M.; *see* Westermeyer, J.F.
Harvey, P.D.; *see* Neale, J.M.
Heinrichs, D.W.; Hanlon, T.E.; and Carpenter, W.T., Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome, 10(3):388–398, 1984.
Heinrichs, D.W.; *see* Carpenter, W.T., Jr.
Helzer, J.E., and Robins, L.N. Lifetime psychotic symptoms assessed with the DIS (Letter to the Editor), 10(1):4–5, 1984.
Herz, M.I. Boston Psychotherapy Study (Letter to the Editor), 11(4):528–529, 1985.

J

Jones. B.D. Tardive dysmentia: Further comments, 11(2):187–189, 1985.

K

Karno, M.; Burnam, M.A.; Escobar, J.; and Timbers, D. Lifetime psychotic symptoms assessed with the DIS (Letter to the Editor), 10(2):154–156, 1984.
Karon, B.P. The fear of reducing medication, and where have all the patients gone?, 10(4):613–617, 1984.
Karon, B.P. Omission in review of treatment interactions (Letter to the Editor), 11(1):16–17, 1985.
Karov, M.; *see* Lifshitz, M.
Katz, H.M.; *see* Gunderson, J.G.
Kendler, K.S. Diagnostic approaches to schizotypal personality disorder: A historical perspective, 11(4):538–553, 1985.
Kety, S.S. Comments on the NIMH-Israeli high-risk study, 11(3):354–356, 1985.
Kety, S.S. Schizotypal personality disorder: An operational definition of Bleuler's latent schizophrenia? 11(4):590–594, 1985.
Klerman, G.L. Ideology and science in the individual psychotherapy of schizophrenia, 10(4):608–612, 1984.
Knapp, P.H.; *see* Gunderson, J.G.
Knapp, P.H.; *see* Stanton, A.H.
Kugelmass, S.; Marcus, J.; and Schmueli, J. Psychophysiological reactivity in high-risk children, 11(1):66–73, 1985.
Kugelmass, S.; *see* Lifshitz, M.
Kuipers, L.; *see* Berkowitz, R.

L

Lambe, R.; *see* Chaika, E.
Lanin-Kettering, I., and Harrow, M. The thought behind the words: A view of schizophrenic speech and thinking disorders, 11(1):1–7, 1985.
Lanquetot, R. First person account: Confessions of the daughter of a schizophrenic, 10(3):467–471, 1984.
Lapsley, H.; *see* Hall, W.
Latz, A.; *see* Mirsky, A.F.
Leff, J.; *see* Berkowitz, R.
Lenzenweger, M.F.; *see* Cornblatt, B.A.
Lewine, R.R.J. Negative symptoms in schizophrenia: Editor's introduction, 11(3):361–363, 1985.
Lewine, R.R.J.; *see* Gibbons, R.D.
Lewow, E.; *see* Marcus, J.
Lifshitz, M.; Kugelmass, M.; and Karov, M. Perceptual-motor and memory performance of high-risk children, 11(1):74–84, 1985.
Lifshitz, M.; *see* Nagler, S.
Lubowsky, J.; *see* Bernstein, A.S.
Lukoff, D.; Snyder, K.; Ventura, J.; and

Nuechterlein, K.H. Life events, familial stress, and coping in the developmental course of schizophrenia, 10(2):258–292, 1984.

M

Marcus, J.; Hans, S.L.; Byhouwer, B.; and Norem, J. Relationships among neurological functioning, intelligence quotients, and physical anomalies, 11(1):101–106, 1985.

Marcus, J.; Hans, S.L.; Lewow, E.; Wilkinson, L.; and Burack, C.M. Neurological findings in high-risk children: Childhood assessment and 5-year followup, 11(1):85–100, 1985.

Marcus, J.; *see* Kugelmass, S.

Marcus, J.; *see* Nagler, S.

May, P.R.A. A step forward in research on psychotherapy of schizophrenia, 10(4):604–607, 1984.

Mayer, M.; Alpert, M.; Stastny, P.; Perlick, D.; and Empfield, M. Multiple contributions to clinical presentation of flat affect in schizophrenia, 11(3):420–426, 1985.

McGrath, M.E. First person account: Where did I go?, 10(4):638–640, 1984.

Meltzer, H.Y. Schizoaffective disorder: Is the news of its nonexistence premature? Editor's introduction, 10(1):11–13, 1984.

Meltzer, H.Y.; Arora, R.C.; and Metz, J. Biological studies of schizoaffective disorders, 10(1):49–70, 1984.

Meltzer, H.Y.; *see* Goodnick, P.J.

Merritt, R.D., and Balogh, D.W. Critical stimulus duration: Schizophrenic trait or state?, 11(3):341–343, 1985.

Merom, H.; *see* Ayalon, M.

Merom, H.; *see* Silberman, E.K.

Metz, J.; *see* Meltzer, H.Y.

Mirsky, A.F. Addendum: Bringing the Israeli high-risk study to completion, 11(1):30, 1985.

Mirsky, A.F.; Silberman, E.K.; Latz, A.; and Nagler, S. Adult outcomes of high-risk children: Differential effects of town and kibbutz rearing, 11(1):150–154, 1985.

Mirsky, A.F.; *see* Nagler, S.

Mirsky, A.F.; *see* Silberman, E.K.

Mittleman, G. First person account: The pain of parenthood of the mentally ill, 11(2):300–303, 1985.

Mukherjee, S. Tardive dysmentia: A reappraisal, 10(2):151–152, 1984.

Mukherjee, S., and Bilder, R.M. Commentary, 11(2):189–190, 1985.

Mukherjee, S.; *see* Bilder, R.M.

Müller, C. Psychotherapy in schizophrenia: The end of the pioneers' period, 10(4):618–620, 1984.

Murphy, R.; *see* Oltmanns, T.F.

N

Nagler, S. Overall design and methodology of the Israeli high-risk study, 11(1):31–37, 1985

Nagler, S., and Glueck, Z. The clinical interview, 11(1):38–47, 1985.

Nagler, S.; Marcus, J.; Sohlberg, S.C.; Lifshitz, M.; and Silberman, E.K. Clinical observation of high-risk children, 11(1):107–111, 1985.

Nagler, S., and Mirsky, A.F. Introduction: The Israeli high-risk study, 11(1):19–29, 1985.

Nagler, S.; *see* Mirsky, A.F.

Nagler, S.; *see* Silberman, E.K.

Neale, J.M.; Oltmanns, T.F.; and Harvey, P.D. The need to relate cognitive deficits to specific behavioral referents of schizophrenia, 11(2):286–291, 1985.

Neufeld, R.W.J.; *see* George, L.

Norem, J.; *see* Marcus, J.

Nuechterlein, K.H., and Dawson, M.E. A heuristic vulnerability/stress model of schizophrenic episodes, 10(2):300–312, 1984.

Nuechterlein, K.H., and Dawson, M.E. Increased critical stimulus duration: Vulnerability or episode indicator?, 11(3):344–346, 1985.

Nuechterlein, K.H., and Dawson, M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders, 10(2):160–203, 1984.

Nuechterlein, K.H., and Dawson, M.E. Vulnerability and stress factors in the developmental course of schizophrenic disorders, 10(2):158–159, 1984.

Nuechterlein, K.H.; *see* Dawson, M.E.

Nuechterlein, K.H.; *see* Lukoff, D.

O

Oltmanns, T.F.; Murphy, R.; Berenbaum, H.; and Dunlop, S.R. Rating verbal communication impairment in schizophrenia and affective disorders, 11(2):292–299, 1985.

Oltmanns, T.F.; *see* Neale, J.M.

O'Neal, J.M. First person account: Finding myself and loving it, 10(1):109–110, 1984.

P

Pandurangi, A.K.; *see* Bilder, R.M.

Pava, J.; *see* Bernstein, A.S.

Perlick, D.; *see* Mayer, M.

Pethö, B. Hourglass model of psychiatric diseases: The endogenous psychoses, 10(4):509–519, 1984.

Piercey, B.P. First person account: Making the best of it, 11(1):155–157, 1985.

Pogue-Geile, M.F., and Harrow, M. Negative and positive symptoms in schizophrenia and depression: A followup, 10(3):371–387, 1984.

Pogue-Geile, M.F., and Harrow, M. Negative symptoms in schizophrenia: Their longitudinal course and prognostic importance, 11(3):427–439, 1985.

Pulver, A.E., and Carpenter, W.T., Jr. The authors reply [to Karno et al.] (Letter to the Editor), 10(2):156–157, 1984.

Pulver, A.E.; *see* Carpenter, W.T., Jr.

R

Riedel, J.A.; *see* Bernstein, A.S.

Rieder, R.O.; *see* Bilder, R.M.

Robins, L.N.; *see* Helzer, J.E.

Rosenthal, R.; *see* Stanton, A.H.

S

Schmueli, J.; *see* Kugelmass, S.

Schnitzer, R.; *see* Stanton, A.H.;

Schnur, D.; *see* Bernstein, A.S.

Schooler, N.R.; *see* Gibbons, R.D.

Shotten, J.H. The family interview, 11(1):112–116, 1985.

Shotten, J.H.; *see* Silberman, E.K.

Siever, L.J. Biological markers in schizotypal personality disorders, 11(4):564–575, 1985.

Siever, L.J.; *see* Gunderson, J.G.

Silberman, E.K., and Mirsky, A.F. The NIMH-Israeli schizophrenia project: The history of a high-risk study, 11(1):146–149, 1985.

Silberman, E.K.; Nagler, S.; Ayalon, M.; Shotten, J.H.; and Merom, H. Clinical-subjective evaluation of high-risk children: Integration and discussion, 11(1):121–128, 1985.
Silberman, E.K., and Tassone, E.P. The Israeli high-risk study: Statistical overview and discussion, 11(1):138–145, 1985.
Silberman, E.K.; *see* Mirsky, A.F.
Silberman, E.K.; *see* Nagler, S.
Silove, D.; *see* Hall, W.
Simpson, J.C.; *see* Tsuang, M.T.
Snyder, K.; *see* Lukoff, D.
Sohlberg, S.C. Personality and neuropsychological performance of high-risk children, 11(1):48–60, 1985.
Sohlberg, S.C., and Yaniv, S. Social adjustment and cognitive performance of high-risk children, 11(1):61–65, 1985.
Sohlberg, S.C.; *see* Nagler, S.
Sommers, A.A. "Negative symptoms": Conceptual and methodological problems, 11(3):364–379, 1985.
Stakes, M. First person account: Becoming seaworthy, 11(4):629–630, 1985.
Stanton, A.H.; Gunderson, J.G.; Knapp, P.H.; Frank, A.F.; Vannicelli, M.L.; Schnitzer, R.; and Rosenthal, R. Effects of psychotherapy in schizophrenia: I. Design and implementation of a controlled study, 10(4):520–563, 1984.
Stastny, P.; *see* Mayer, M.
Stone, M. Schizotypal personality: Psychotherapeutic aspects, 11(4):576–589, 1985.
Strauss, J.S. Negative symptoms: Future developments of the concept, 11(3):457–460, 1985.
Strauss, J.S.; Harding, C.M.; and **Weissman, M.M.** Vulnerability to depressive and schizophrenic disorders—Conference report, 10(3):460–465, 1984.
Struening, E.; *see* Beels, C.C.

T

Tassone, E.P.; *see* Silberman, E.K.
Timbers, D.; *see* Karno, M.
Torgersen, S. Relationship of schizotypal personality disorder to schizophrenia: Genetics, 11(4):554–563, 1985.
Tsuang, M.T., and Simpson, J.C. Schizo-affective disorder: Concept and reality, 10(1):14–25, 1984.

U

Uchtenhagen, A. Schizophrenia-like results among the consanguine relatives of schizophrenics, 11(4):612–628, 1985.

V

Vannicelli, M.L.; *see* Gunderson, J.G.
Vannicelli, M.L.; *see* Stanton, A.H.
Ventura, J.; *see* Lukoff, D.

W

Walker, E.; *see* Aylward, E.
Wallace, C.J. Community and interpersonal functioning in the course of schizophrenic disorders, 10(2):233–257, 1984.
Weissman, M.M.; *see* Strauss, J.S.
Westermeyer, J.F., and Harrow, M. Prognosis and outcome using broad (*DSM-II*) and narrow (*DSM-III*) concepts of schizophrenia, 10(4):624–637, 1984.
Wilkinson, L.; *see* Marcus, J.

Y

Yaniv, S.; *see* Sohlberg, S.C.

Z

Zubin, J. Negative symptoms: Are they indigenous to schizophrenia?, 11(3):461–470, 1985.

Subject Index

A

Akinesia
Tardive dysmentia and frontal lobe disorder, 11:255

Attention
Backward masking in schizotypal personality disorder, 11:564
Critical stimulus duration, 10:160; 11:341; 11:344
High-risk studies, 10:161
Positive/negative symptoms of schizophrenia, 11:397
Schizophrenic patients in remission, 10:161
Smooth pursuit eye tracking, in 10:49; 11:564
Symptomatic schizophrenic patients, 10:161

Attention deficit disorder psychosis
Diagnostic entity, 11:523
Treatment, 11:523

Autobiographical accounts
Daughter's account of schizophrenic mother, 10:467
Mother's account of schizophrenic son, 11:155, 11:300
Narrative account of contacts with two subjects in Israeli high-risk study by project secretary, 11:129
Schizophrenic patients' accounts of experiences, 10:109; 10:638; 11:487; 11:629

B

Biological factors
Cerebral blood flow, 11:191

Computed tomography, 10:49; 11:191; 11:255; 11:471
Dopamine, 10:49; 11:191; 11:255; 11:471; 11:564
Kindling, 11:191
Neural plasticity, 11:191
Neuromuscular abnormalities, 10:49
Noradrenergic measure, 10:49
Platelet monoamine oxidase, 10:49; 11:564
Positron emission tomography, 11:191; 11:255
Schizoaffective disorder, 10:49
Schizotypal personality disorder, 11:564
Serotonergic measures, 10:49
Sleep measures, 10:49
Smooth pursuit eye movements, 10:49; 11:564

Brainstem

Isodendritic core, involvement in schizophrenia, 10:1

C

Cognition

Deficits related to behavioral referents in schizophrenia, 11:286
Perceptual/motor abnormalities, 11:264
Performance in Israeli high-risk study, 11:61
Relationship to symptomatology in schizophrenia, 11:264

Community functioning

Course of schizophrenic disorder, 10:233
Quality of Life Scale, 10:388

Continuous Performance Test

High-risk studies, 10:161

Critical stimulus duration

Schizophrenic trait or state, 10:160; 11:341; 11:344

D

Defect state

Negative symptoms, 11:409
Neuropathology, 11:409
Quality of Life Scale, 10:388

Developmental course of schizophrenic disorders, 10:158–312

Attention, 10:161
Information processing, 10:161
Psychophysiology, 10:204
Stress, 10:158
Vulnerability, 10:158

Diagnosis

DSM–II vs. *DSM–III* in outcome assessment, 10:624
Schizotypal personality disorder, 11:538; 11:595

Diagnostic Interview Schedule

Methodological issues, 10:4; 10:5
Lifetime psychotic symptoms, 10:154; 10:156

E

Economic costs of schizophrenia, 11:598

Education

Educating relatives of schizophrenic patients about the disorder, 10:418

Electrodermal response

Developmental course of schizophrenic disorders, 10:204

Electroencephalogram

Alpha blocking, 11:230

Endogenous psychoses

Hourglass model of psychiatric disease, 10:509

Expressed emotion

Educating relatives about factors affecting relapse, 10:418
Relapse, stress, 10:258

F

Family

Abnormal personality traits in relatives of schizophrenic patients, 11:538
Education of relatives of schizophrenics, 10:418
Expressed emotion, 10:258
Family factors in the developmental course of schizophrenic disorders, 10:258
Family interview in Israeli high-risk study, 11:112
Relapse, 10:258
Rorschach findings in relatives of schizophrenic patients, 11:612
Schizotypal personality disorder in relatives of schizophrenic patients, 11:538; 11:554; 11:564; 11:576
Stress, 10:258

Flat affect

Multiple contributors to, 11:420
Right hemispheric function, 11:420

Frontal lobe disorder

Akinesia, tardive dysmentia, and schizophrenia, 11:255

G

Galvanic skin response

In Israeli high-risk study, 11:66

Genetics

Definition of samples at high risk for schizophrenia, 10:204
Schizoaffective disorder, 10:26
Schizophrenia, 11:191
Schizotypal personality disorder, 11:554; 11:590

Grants

Schizophrenia-related research, fiscal year 1982, 10:313
Schizophrenia-related research, fiscal year 1983, 11:631

H

High-risk studies. *See also* Israeli high-risk study

Attention and information processing, 10:161
Biological high-risk strategy, 11:564
Community and interpersonal functioning, 10:233
Psychophysiology, 10:233

Hourglass model of psychiatric disease, 10:509

I

Information processing

Backward masking, 11:564
Critical stimulus duration, 10:160; 11:341; 11:344
High-risk studies, 10:161
Negative/positive symptoms of schizophrenia, 11:397
Remitted and symptomatic schizophrenic patients, 10:161

Intelligence

Israeli high-risk study assessments, 11:48

Relationship to schizophrenia, 10:430

Interpersonal functioning

Course of schizophrenia, 10:233

Israeli high-risk study

Background, 11:19; 11:30
Case descriptions, 11:129
Clinical interview, 11:38
Clinical observation of children, 11:107
Clinical/subjective evaluation, 11:121
Cognitive performance, 11:61
Commentaries, 11:347; 11:349; 11:354; 11:358
Design and methodology, 11:31
Family interview, 11:113
History, 11:146
Intelligence, 11:101
Kibbutz vs. town rearing, 11:150
Memory, 11:74
Neurological findings, 11:85; 11:101
Neuropsychological measures, 11:48
Outcome in adulthood, 11:150
Perceptual-motor findings, 11:74
Personality measures, 11:48
Physical anomalies, 11:101
Psychophysiology, 11:66
Social adjustment, 11:61
Statistical overview, 11:138
Teacher interview, 11:117

K

Kindling

Neural plasticity and, 11:191

L

Language

Rating in schizophrenia and affective disorder, 11:292
Speech vs. thought disorder, 11:1; 11:8

Life events

Course of schizophrenic disorder, 10:258

M

Motor anomalies, 11:264

N

National Institute of Mental Health (NIMH)

NIMH-Israeli high-risk study, 11:19–154
Schizophrenia-related research grants, fiscal year 1982, 10:313
Schizophrenia-related research grants, fiscal year 1983, 11:631

Negative/positive symptoms of schizophrenia, 10:371; 11:361–486

Assessment of negative vs. positive symptoms, 11:380
Attention and information processing, 11:397
Commentaries, 11:457; 11:461; 11:471
Computed tomography, 11:380; 11:471
Conceptual and methodological problems, 11:364; 11:380
Factor analysis, 11:390
Followup, assessing stability of symptoms in schizophrenia and depression, 10:371
Future development of concept, 11:457
Kraepelinian vs. Bleulerian view, 11:390
Longitudinal course, 11:427
Neuroleptic response, 11:453; 11:471
Neuropsychological correlates, 11:409
Prognostic importance, 11:427
Role functioning, 10:371
Secondary vs. primary negative symptoms, 11:440
Type I–II schizophrenia, 11:471

Neural plasticity, 11:191

Neuropsychology

Defect state, 11:409
Negative symptoms, 11:409

O

Orienting response, 10:204

Schizophrenia vs. depression, 11:230

Outcome

Broad (*DSM-II*) vs. narrow (*DSM-III*) criteria and, 10:624
Negative/positive symptoms, 11:427
Psychotherapy of schizophrenia, 10:564
Relapse, 10:293
Schizoaffective disorder, 10:87
Schizotypal personality disorder, 11:576

P

Perceptual anomalies, 11:264

Pharmacotherapy

Attention deficit disorder psychosis, 11:523
Compliance, 10:412
Deficit state, 11:453
Developing and maintaining adherence to long-term regimens, 10:412
Negative symptoms, 11:453
Schizoaffective disorder, 10:30

Prognosis

Broad (*DSM-II*) vs. narrow (*DSM-III*) criteria, 10:624
Community and interpersonal functioning, 10:233
Negative/positive symptoms, 11:427
Schizoaffective disorder, 11:427

Psychophysiology

Developmental course of schizophrenic disorders, 10:204
High-risk studies, 10:204; 11:66
Israeli high-risk study, 11:66
Remitted and symptomatic schizophrenic subjects, 10:204
Schizophrenia vs. depression, orienting response dysfunction, 11:230
Skin conductance, orienting response, 10:204
Reaction time, 10:161; 11:66; 11:230

Psychotherapy of schizophrenia, 10:520–623

Commentaries on Boston Psychotherapy Study, 10:599; 10:604; 10:608; 10:613; 10:618; 10:621
Design and implementation of outcome study, 10:521
Expressive, insight-oriented psychotherapy, 10:521; 10:564
Interactions between drug and psychosocial treatment, 11:16; 11:17
Outcome, 10:564; 11:528
Reality-adaptive, supportive therapy, 10:521; 10:564
Schizotypal personality disorder, 11:576
Therapist characteristics, 10:521

Q

Quality of Life Scale

Schizophrenic deficit syndrome, 10:388

R

Reaction time

High-risk studies, 10:161; 11:66
Schizophrenia vs. depression, 11:230

Relapse

Definition, 10:293
Outcome research, 10:293

Remission

Attention and information processing during, 10:161
Psychophysiological findings concerning, 10:204

Rorschach test

Schizophrenia-like responses in relatives of schizophrenics, 11:612

S

Schizoaffective disorder, 10:11–108

Biological studies, 10:49
Conceptual issues, 10:14
Family studies, 10:14, 10:26
Genetic studies, 10:26
Outcome, 10:97
Pharmacotherapy, 10:30
Prognosis, 10:87
Relationship to schizophrenia vs. affective disorder, 10:11; 10:14; 10:26; 10:30; 10:49; 10:87
Vulnerability, two-factor model, 10:71

Schizotypal personality disorder, 11:532–597

Backward-masking performance, 11:564
Biological markers, 11:564
Bleuler's latent schizophrenia, 11:590
Borderline personality disorder, 11:538
Borderline schizophrenia, 11:538
Case descriptions, 11:576
Clinical model, 11:538; 11:564
Commentaries, 11:590; 11:595
Diagnosis, 11:538; 11:595
Familial model, 11:538; 11:564
Genetic relationship to schizophrenia, 11:554; 11:590
Historical background of concept, 11:538; 11:590
Outcome, 11:576
Platelet monoamine oxidase, 11:564
Psychotherapy, 11:576
Relatedness to schizophrenia, 11:532; 11:538; 11:554; 11:564; 11:590
Smooth pursuit eye movements, 11:564

Skin conductance

Developmental course of schizophrenic disorders, 10:204
Schizophrenia vs. depression, 11:230

Social support

Environmental buffer, 10:258
Measurements of, 10:399

Speech

Rating in schizophrenia and affective disorders, 11:292
Schizophrenic speech vs. schizophrenic thinking, 11:1; 11:8
Thought disorder in schizophrenia, 11:1; 11:8

Stress

Familial contributors, 10:258
Developmental course of schizophrenia, 10:258
Life events, 10:258

T

Tardive dysmentia, 10:151; 10:152; 11:187; 11:189; 11:255

Teacher

Assessments of subjects in Israeli high-risk study, 11:112

Thought disorder

Rating in schizophrenia and affective disorder, 11:292
Relationship to speech, language, 11:1; 11:8

Treatment. *See also* Pharmacotherapy, Psychotherapy

Educating relatives of schizophrenic patients as part of treatment process, 10:418
Negative symptoms, 11:440
Schizoaffective disorder, 10:30
Social support, 10:258

V

Verbal communication impairment

Ratings in schizophrenia and affective disorders, 11:292

Vulnerability

Attention, 10:161
Developmental course of schizophrenic disorders, 10:158
Increased critical stimulus duration, 10:160; 11:341; 11:344
Information processing, 10:161
Questionnaire-defined, 11:341
Research on vulnerability to depressive and schizophrenic disorders, report on Yale conference, 10:460
Schizoaffective disorder, two-factor model, 10:71
Stress, 10:158

Vulnerability/stress model of schizophrenic episodes, 10:300

W

What is schizophrenia?

Opinions from authorities, 10:8; 10:367; 10:368; 10:369

*U.S. GOVERNMENT PRINTING OFFICE: 1985-461-353:20003